Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans

In response to the Ebola virus (EBOV) crisis of 2013–2016, a recombinant vesicular stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune r...

Descripción completa

Detalles Bibliográficos
Autores principales: Poetsch, Joseph H, Dahlke, Christine, Zinser, Madeleine E, Kasonta, Rahel, Lunemann, Sebastian, Rechtien, Anne, Ly, My L, Stubbe, Hans C, Krähling, Verena, Biedenkopf, Nadine, Eickmann, Markus, Fehling, Sarah K, Olearo, Flaminia, Strecker, Thomas, Sharma, Piyush, Lang, Karl S, Lohse, Ansgar W, Schmiedel, Stefan, Becker, Stephan, Addo, Marylyn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350948/
https://www.ncbi.nlm.nih.gov/pubmed/30452666
http://dx.doi.org/10.1093/infdis/jiy565
Descripción
Sumario:In response to the Ebola virus (EBOV) crisis of 2013–2016, a recombinant vesicular stomatitis virus (VSV)–based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.

Ejemplares similares